Related references
Note: Only part of the references are listed.Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population
Mayur Parkhi et al.
APMIS (2022)
High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma
Joaquim Carreras et al.
CANCER SCIENCE (2022)
Clinicopathological risk factors for a poor prognosis of primary central nervous system lymphoma in elderly patients in the Tohoku and Niigata area: a multicenter, retrospective, cohort study of the Tohoku Brain Tumor Study Group
Kenichiro Asano et al.
BRAIN TUMOR PATHOLOGY (2022)
Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
Daniel J. Garcia-Dominguez et al.
CANCERS (2022)
NR1H3 (LXRα) is associated with pro-inflammatory macrophages, predicts survival and suggests potential therapeutic rationales in diffuse large b-cell lymphoma
Maria Carmela Vegliante et al.
HEMATOLOGICAL ONCOLOGY (2022)
Targeting CD47 for cancer immunotherapy
Zhongxing Jiang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures
Nikita Kotlov et al.
CANCER DISCOVERY (2021)
SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status
G. A. Croci et al.
ANNALS OF ONCOLOGY (2021)
Macrophage Polarization States in the Tumor Microenvironment
Ava J. Boutilier et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Prognostic Value of Survivin in Nasopharyngeal Carcinoma: A Systematic Review and Meta-analysis
Wenji Xie et al.
JOURNAL OF CANCER (2021)
A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL
Annette M. Staiger et al.
LEUKEMIA (2020)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Inflammatory Cells in Diffuse Large B Cell Lymphoma
Roberto Tamma et al.
JOURNAL OF CLINICAL MEDICINE (2020)
The tumor microenvironment
Nicole M. Anderson et al.
CURRENT BIOLOGY (2020)
Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
Da-Ke Li et al.
ONCOLOGY LETTERS (2020)
Poly(I:C) stimulation is superior than Imiquimod to induce the antitumoral functional profile of tumor-conditioned macrophages
Akihiro Maeda et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2019)
Prognostic roles of tumor associated macrophages in bladder cancer: a system review and meta-analysis
Shui-Qing Wu et al.
Oncotarget (2018)
Prognostic implications of tumor-infiltrating macrophages, M2 macrophages, regulatory T-cells, and indoleamine 2,3-dioxygenase-positive cells in primary diffuse large B-cell lymphoma of the central nervous system
Soo Jeong Nam et al.
ONCOIMMUNOLOGY (2018)
Tumor-Derived CCL2 Mediates Resistance to Radiotherapy in Pancreatic Ductal Adenocarcinoma
Anusha Kalbasi et al.
CLINICAL CANCER RESEARCH (2017)
Lymphocyte-to-monocyte ratio is associated with prognosis of diffuse large B-cell lymphoma: correlation with CD163 positive M2 type tumor-associated macrophages, not PD-1 positive tumor-infiltrating lymphocytes
Jingxuan Wang et al.
ONCOTARGET (2017)
Prognostic significance of tumor-associated macrophages in ovarian cancer: A meta-analysis
Xia Yuan et al.
GYNECOLOGIC ONCOLOGY (2017)
Implications of infiltrating immune cells within bone marrow of patients with diffuse large B-cell lymphoma
Juhyeon Jeong et al.
HUMAN PATHOLOGY (2017)
Tumour-associated macrophages as treatment targets in oncology
Alberto Mantovani et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2017)
The Prognostic and Clinicopathological Significance of Tumor-Associated Macrophages in Patients with Gastric Cancer: A Meta-Analysis
Songcheng Yin et al.
PLOS ONE (2017)
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles et al.
ADVANCES IN THERAPY (2017)
Prognostic Impact of Tumor Microenvironment in Diffuse Large B-Cell Lymphoma Uniformly Treated With R-CHOP Chemotherapy
Juan C. Gomez-Gelvez et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2016)
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
Steven H. Swerdlow et al.
BLOOD (2016)
Meta-analysis of the prognostic and clinical value of tumor-associated macrophages in adult classical Hodgkin lymphoma
Baoping Guo et al.
BMC MEDICINE (2016)
CCL2 as a potential therapeutic target for clear cell renal cell carcinoma
Ryuichiro Arakaki et al.
CANCER MEDICINE (2016)
New Mechanisms of Tumor-Associated Macrophages on Promoting Tumor Progression: Recent Research Advances and Potential Targets for Tumor Immunotherapy
Qiujun Guo et al.
JOURNAL OF IMMUNOLOGY RESEARCH (2016)
Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Michael Zhang et al.
PLOS ONE (2016)
Toll-like receptor 4-induced inflammatory responses contribute to the tumor-associated macrophages formation and infiltration in patients with diffuse large B-cell lymphoma
Xiaofang Wang et al.
ANNALS OF DIAGNOSTIC PATHOLOGY (2015)
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upaEuro
H. Tilly et al.
ANNALS OF ONCOLOGY (2015)
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad et al.
LEUKEMIA & LYMPHOMA (2015)
Prognostic influence of macrophages in patients with diffuse large B-cell lymphoma: a correlative study from a Nordic phase II trial
Sari Riihijarvi et al.
HAEMATOLOGICA (2015)
High density of CD68+/CD163+tumour-associated macrophages (M2-TAM) at diagnosis is significantly correlated to unfavorable prognostic factors and to poor clinical outcomes in patients with diffuse large B-cell lymphoma
Francesco Marchesi et al.
HEMATOLOGICAL ONCOLOGY (2015)
Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy
Carola H. Ries et al.
CANCER CELL (2014)
Human leukocyte antigen-DR expression on flow cytometry and tumor-associated macrophages in diffuse large B-cell lymphoma treated by rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy: retrospective cohort study
Wataru Yamamoto et al.
LEUKEMIA & LYMPHOMA (2014)
An increase of M2 macrophages predicts poor prognosis in patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone
Soo Jeong Nam et al.
LEUKEMIA & LYMPHOMA (2014)
Clinical Significance of sIL-2R Levels in B-Cell Lymphomas
Noriaki Yoshida et al.
PLOS ONE (2013)
High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma
Qi-chun Cai et al.
MEDICAL ONCOLOGY (2012)
The Stromal Cell Marker SPARC Predicts for Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
Paul N. Meyer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2011)
Association of CD57+Natural Killer Cells with Better Overall Survival in DLBCL Patients
Jeong Hyeon Lee et al.
KOREAN JOURNAL OF PATHOLOGY (2011)
Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
Bertrand Coiffier et al.
BLOOD (2010)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone
Minna Taskinen et al.
CLINICAL CANCER RESEARCH (2007)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Share Paper
